Tandem Diabetes Care Inc. (TNDM) reported first-quarter 2026 results with total revenue rising to $247.2 million, up 5.5% year-over-year, while gross profit improved to $136.8 million, a 15.5% increase.
Diluted earnings per share were -$0.30, versus an estimate of -$0.45, and revenue slightly exceeded the street estimate of $245.2 million, representing a modest beat on both top and bottom lines.
Following the release, TNDM's stock moved about 7.4% since market close.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Tandem Diabetes Care Inc. Insider Trading Activity
Tandem Diabetes Care Inc. insiders have traded $TNDM stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $TNDM stock by insiders over the last 6 months:
- MARK DAVID NOVARA (EVP & CHIEF COMMERCIAL OFFICER) has made 0 purchases and 2 sales selling 189 shares for an estimated $4,355.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
Tandem Diabetes Care Inc. Hedge Fund Activity
We have seen 108 institutional investors add shares of Tandem Diabetes Care Inc. stock to their portfolio, and 151 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HOOD RIVER CAPITAL MANAGEMENT LLC removed 2,551,644 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $56,085,135
- CITADEL ADVISORS LLC added 2,048,802 shares (+5147.6%) to their portfolio in Q4 2025, for an estimated $45,032,667
- UBS GROUP AG added 1,629,968 shares (+390.1%) to their portfolio in Q1 2026, for an estimated $31,246,486
- DRIEHAUS CAPITAL MANAGEMENT LLC added 1,610,342 shares (+inf%) to their portfolio in Q4 2025, for an estimated $35,395,317
- MORGAN STANLEY added 1,342,950 shares (+182.1%) to their portfolio in Q4 2025, for an estimated $29,518,041
- FIRST LIGHT ASSET MANAGEMENT, LLC added 1,089,493 shares (+inf%) to their portfolio in Q4 2025, for an estimated $23,947,056
- ASSENAGON ASSET MANAGEMENT S.A. removed 1,049,216 shares (-85.5%) from their portfolio in Q1 2026, for an estimated $20,113,470
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Tandem Diabetes Care Inc. Congressional Stock Trading
Members of Congress have traded $TNDM stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $TNDM stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 03/03.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.
Tandem Diabetes Care Inc. Analyst Ratings
Wall Street analysts have issued reports on $TNDM in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Baird issued a "Outperform" rating on 12/16/2025
- Barclays issued a "Overweight" rating on 11/10/2025
To track analyst ratings and price targets for Tandem Diabetes Care Inc., check out Quiver Quantitative's $TNDM forecast page.
Tandem Diabetes Care Inc. Price Targets
Multiple analysts have issued price targets for $TNDM recently. We have seen 15 analysts offer price targets for $TNDM in the last 6 months, with a median target of $28.0.
Here are some recent targets:
- Mathew Blackman from TD Cowen set a target price of $28.0 on 04/20/2026
- David Roman from Goldman Sachs set a target price of $25.0 on 04/09/2026
- Richard Newitter from Truist Securities set a target price of $35.0 on 03/19/2026
- Matt O'Brien from Piper Sandler set a target price of $33.0 on 03/17/2026
- Patrick Wood from Morgan Stanley set a target price of $25.0 on 03/02/2026
- Frank Takkinen from Lake Street set a target price of $50.0 on 02/23/2026
- Danielle Antalffy from UBS set a target price of $22.0 on 02/20/2026
